Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Gilead Sciences (GILD)
:GILD
Holding GILD?
Track your performance easily
GILD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$62.07 - $98.90
Previous CloseN/A
Volume1.95M
Average Volume (3M)6.89M
Market Cap
$114.22B
Enterprise Value$121.60B
Total Cash (Recent Filing)$11.89B
Total Debt (Recent Filing)$26.35B
Price to Earnings (P/E)1033.3
Beta0.59
Next Earnings
Feb 11, 2025EPS Estimate
1.71Last Dividend Ex-Date
Dec 13, 2024Dividend Yield3.36%
Share Statistics
EPS (TTM)0.09
Shares Outstanding1,246,265,900
10 Day Avg. Volume7,060,256
30 Day Avg. Volume6,886,209
Standard Deviation0.07
R-Squared0.02
Alpha0.00956
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)4.04
Price to Cash Flow (P/CF)6.60
P/FCF Ratio6.90
Enterprise Value/Market Cap1.06
Enterprise Value/Revenue4.30
Enterprise Value/Gross Profit5.90
Enterprise Value/Ebitda35.31
Forecast
1Y Price Target
$99.29Price Target Upside8.11% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering26
Gilead Sciences News
Bulls Say, Bears Say
Bulls Say
HIV Prevention MarketManagement expressed confidence in growing the prevention (PrEP) market, aiming for above 12-13% annual growth.
Pipeline DevelopmentsPositive pipeline developments for Lenacapavir (LEN) in HIV prevention and anito-cel in multiple myeloma indicate potential for upward estimate revisions and further multiple expansion.
Stock ValuationShares of Gilead Sciences are trading at a lower P/E ratio compared to the biopharma peer group average, indicating potential undervaluation.
Bears Say
Competitive PressureYescarta CAR-T therapy is facing increasing competition, which is expected to create headwinds going into the future.
Drug Development ChallengesThe decision to withdraw Trodelvy from U.S. accelerated approval in 2LmUC adds to the challenges faced by Gilead's solid-tumor franchise.
Policy ChangesPotential policy changes regarding Medicaid budgets that impact HIV therapies are considered a significant risk to the company's outlook.
---
Ownership Overview
0.08% Insiders
30.41% Mutual Funds
0.56% Other Institutional Investors
42.11% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
ProductionRisks related to the company’s ability to manufacture goods and services
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
GILD FAQ
What was Gilead Sciences’s price range in the past 12 months?
Gilead Sciences lowest stock price was $62.07 and its highest was $98.90 in the past 12 months.
What is Gilead Sciences’s market cap?
Gilead Sciences’s market cap is $114.22B.
When is Gilead Sciences’s upcoming earnings report date?
Gilead Sciences’s upcoming earnings report date is Feb 11, 2025 which is in 23 days.
How were Gilead Sciences’s earnings last quarter?
Gilead Sciences released its earnings results on Nov 06, 2024. The company reported $2.02 earnings per share for the quarter, beating the consensus estimate of $1.53 by $0.49.
Is Gilead Sciences overvalued?
According to Wall Street analysts Gilead Sciences’s price is currently Undervalued.
Does Gilead Sciences pay dividends?
Gilead Sciences pays a Quarterly dividend of $3.076 which represents an annual dividend yield of 3.36%. See more information on Gilead Sciences dividends here
What is Gilead Sciences’s EPS estimate?
Gilead Sciences’s EPS estimate is 1.71.
How many shares outstanding does Gilead Sciences have?
Gilead Sciences has 1,246,265,900 shares outstanding.
What happened to Gilead Sciences’s price movement after its last earnings report?
Gilead Sciences reported an EPS of $2.02 in its last earnings report, beating expectations of $1.53. Following the earnings report the stock price went up 6.775%.
Which hedge fund is a major shareholder of Gilead Sciences?
Among the largest hedge funds holding Gilead Sciences’s share is Dodge & Cox. It holds Gilead Sciences’s shares valued at 3B.
---
Gilead Sciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$99.29 (8.11% Upside)
$99.29 (8.11% Upside)
Blogger Sentiment
Bullish
GILD Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 1.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $15.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 0.1%
Last 30 Days ▼ 0.9%
Last 30 Days ▼ 0.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
10.53%
12-Months-Change
Fundamentals
Return on Equity
0.62%
Trailing 12-Months
Asset Growth
-12.58%
Trailing 12-Months
Company Description
Gilead Sciences
Founded in 1987, California-based Gilead Sciences, Inc. is a biopharmaceutical company, which focuses on the research, development, and commercialization of antiviral drugs used in the treatment of diseases like human immunodeficiency virus (HIV), hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi. It offers its products under brands including Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi.
---
GILD Company Deck
---
GILD Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a generally positive outlook with strong revenue growth across key segments like HIV and oncology. The company showed progress in its pipeline with promising drug candidates and improved financial guidance for 2024. However, there were challenges in the cell therapy segment and a significant impairment charge impacting financial results.Read More>---
GILD Revenue Breakdown
67.03% HIV
8.05% Veklury
6.89% Cell Therapy
6.52% HCV
11.51% Other
---
GILD Stock 12 Month Forecast
Average Price Target
$99.29
▲(8.11% Upside)
Technical Analysis
Amgen
―
Bristol-Myers Squibb
―
Vertex Pharmaceuticals
―
Regeneron
―
Incyte
―
Merck & Company
―
Best Analysts Covering GILD
1 Year
1 Year Success Rate
40/63 ratings generated profit
1 Year Average Return
+9.70%
assigned a buy rating last month
Copying Salim Syed's trades and holding each position for 1 Year would result in 63.49% of your transactions generating a profit, with an average return of +9.70% per trade.
---